RU2020108281A3 - - Google Patents

Download PDF

Info

Publication number
RU2020108281A3
RU2020108281A3 RU2020108281A RU2020108281A RU2020108281A3 RU 2020108281 A3 RU2020108281 A3 RU 2020108281A3 RU 2020108281 A RU2020108281 A RU 2020108281A RU 2020108281 A RU2020108281 A RU 2020108281A RU 2020108281 A3 RU2020108281 A3 RU 2020108281A3
Authority
RU
Russia
Application number
RU2020108281A
Other languages
Russian (ru)
Other versions
RU2020108281A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020108281A publication Critical patent/RU2020108281A/ru
Publication of RU2020108281A3 publication Critical patent/RU2020108281A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
RU2020108281A 2017-08-17 2018-08-16 Новые ацилированные аналоги инсулина и варианты их применения RU2020108281A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17186612.2 2017-08-17
EP17186612 2017-08-17
EP17204872.0 2017-12-01
EP17204872 2017-12-01
PCT/EP2018/072191 WO2019034726A1 (en) 2017-08-17 2018-08-16 NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF

Publications (2)

Publication Number Publication Date
RU2020108281A RU2020108281A (ru) 2021-08-26
RU2020108281A3 true RU2020108281A3 (enExample) 2022-03-09

Family

ID=63165388

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020108281A RU2020108281A (ru) 2017-08-17 2018-08-16 Новые ацилированные аналоги инсулина и варианты их применения

Country Status (19)

Country Link
US (2) US10919949B2 (enExample)
EP (1) EP3668892A1 (enExample)
JP (2) JP2020531451A (enExample)
KR (1) KR20200038502A (enExample)
CN (1) CN111032685A (enExample)
AU (1) AU2018317810A1 (enExample)
BR (1) BR112020002364A2 (enExample)
CA (1) CA3071686A1 (enExample)
CL (1) CL2020000310A1 (enExample)
CO (1) CO2020002500A2 (enExample)
IL (1) IL272394A (enExample)
MA (1) MA49896A (enExample)
MX (1) MX2020001434A (enExample)
PE (1) PE20211264A1 (enExample)
PH (1) PH12020550050A1 (enExample)
RU (1) RU2020108281A (enExample)
SG (1) SG11202001077UA (enExample)
TW (1) TW201917134A (enExample)
WO (1) WO2019034726A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JPWO2024185897A1 (enExample) * 2023-03-09 2024-09-12

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5616729A (en) 1986-07-17 1997-04-01 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DK33591D0 (enExample) 1991-02-27 1991-02-27 Novo Nordisk As
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
ATE317443T1 (de) 1996-12-20 2006-02-15 Novo Nordisk As N-terminal verlängerte proteine exprimiert in hefe
JP2002535287A (ja) 1999-01-26 2002-10-22 イーライ・リリー・アンド・カンパニー 単分散性６量体のアシル化されたインスリンアナログ製剤
CA2372393A1 (en) 1999-05-19 2000-11-23 Bassil I. Dahiyat Novel proteins with insulin-like activity useful in the treatment of diabetes
RU2283846C2 (ru) 1999-12-29 2006-09-20 Ново Нордиск А/С Предшественник инсулина, способ его получения и применение
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
EP2376099A4 (en) 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
WO2011003820A1 (de) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
WO2011159882A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Novel stabilized insulin agonists
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011163460A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
WO2013093009A1 (en) 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
EP3024447A1 (en) 2013-07-24 2016-06-01 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
AU2015349890B2 (en) 2014-11-21 2018-08-30 Merck Sharp & Dohme Llc Insulin receptor partial agonists
JP6737793B2 (ja) 2015-01-29 2020-08-12 ノヴォ ノルディスク アー／エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
EP3268384B1 (en) 2015-03-10 2021-11-03 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
EP3280450A4 (en) 2015-04-08 2018-12-12 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
EP3341401A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN108368163A (zh) * 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
WO2017040363A1 (en) 2015-09-02 2017-03-09 Merck Sharp & Dohme Corp. A process for obtaining insulin with correctly formed disulfide bonds

Also Published As

Publication number Publication date
MA49896A (fr) 2020-06-24
US20210094999A1 (en) 2021-04-01
EP3668892A1 (en) 2020-06-24
US10919949B2 (en) 2021-02-16
CA3071686A1 (en) 2019-02-21
MX2020001434A (es) 2020-03-20
JP2022105082A (ja) 2022-07-12
SG11202001077UA (en) 2020-03-30
WO2019034726A1 (en) 2019-02-21
AU2018317810A1 (en) 2020-03-19
IL272394A (en) 2020-03-31
US20190194285A1 (en) 2019-06-27
CO2020002500A2 (es) 2020-06-09
JP2020531451A (ja) 2020-11-05
TW201917134A (zh) 2019-05-01
KR20200038502A (ko) 2020-04-13
BR112020002364A2 (pt) 2020-09-01
CN111032685A (zh) 2020-04-17
PH12020550050A1 (en) 2020-10-19
CL2020000310A1 (es) 2020-07-10
PE20211264A1 (es) 2021-07-15
RU2020108281A (ru) 2021-08-26

Similar Documents

Publication Publication Date Title
BR122021000189A2 (enExample)
BR112019008823A2 (enExample)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020009729B1 (pt) Inibidores de acss2 e métodos de uso dos mesmos
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019014127B1 (pt) Composição farmacêutica para tratamento de tumores
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR102017026429B1 (pt) Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros
BR112020006250B1 (pt) Primeira estação base e método de controle de estado em uma primeira estação base
BR112020009084B1 (pt) Método de operação de um nó de rádio alvo, nó de rádio alvo, método de operação de um nó de rádio de transmissão, nó de rádio de transmissão, e, meio de armazenamento não transitório legível por computador
BR112020007888B1 (pt) Terminal e método de radiocomunicação para um terminal
BR112019024070B1 (pt) Método de ingestão e de distribuição de mídia, aparelho empacotador de mídia, servidor de origem, nó de ponto terminal, e, rede de transmissão contínua em mídia
BR112020011746B1 (pt) Composto, composição farmacêutica, e uso de tal composto
BR122021014832A2 (enExample)
BR112019023437B1 (pt) Partículas sólidas, uso e comprimidos compactados compreendendo as mesmas
CN304009273S (zh) 鞋子（zoenn‑l2m16300‑5）
CN303999594S (zh) 搅拌机（运动型607）